EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis

Audrey Lasek iD, Nathalia Bellon iD, Stéphanie Mallet, Hélène Aubert iD, Carine Vera, Lamia Achour, Claire Thénié, Randy Prescilla, Claire Abasq-Thomas, Sébastien Barbarot iD

Journal of the European Academy of Dermatology and Venereology · 2025

DOI: 10.1111/jdv.70268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von Audrey Lasek und 9 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Saint Vincent de Paul Hospital, Lille, France. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi, Regeneron Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dupilumab, a human monoclonal anti‐interleukin‐4/13 antibody, is approved for treating severe atopic dermatitis (AD) in children aged 6 months–5 years. It received approval for an Early Access Program (EAP) for children by the French Health Authority in October 2022.

Objective

This EAP aims to evaluate the effectiveness and safety of dupilumab in children (aged 6 months–5 years) with severe AD requiring systemic treatment.

Methods

Cumulative data from the French EAP were analysed. Children with severe AD were administered dupilumab 200 and 300 mg (children ≥5 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedHumansChild, PreschoolInfantMaleFemaleSeverity of Illness IndexQuality of LifeTreatment Outcome

Stichwörter der Autor:innen

Early Access Programatopic dermatitisdupilumabpaediatricreal‐world data

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Dermatology Department, Saint Vincent de Paul Hospital, Lille, France.
  • Dermatology Department, Necker Enfants-Malades Hospital, Paris, France.
  • Dermatology Department, La Timone Hospital (AP-HM), Aix Marseille University, Marseille, France.
  • Dermatology Department, Nantes University, Nantes, France.
  • IVIDATA Life Sciences for Statistics on Behalf of Sanofi, Gentilly, France.
  • Medical Affairs Sanofi, Gentilly, France.

ORCID-Profile: Audrey Lasek, Nathalia Bellon, Hélène Aubert, Sébastien Barbarot

Förderung

  • Sanofi
  • Regeneron Pharmaceuticals Inc

Zitieren

APA

Lasek, A., Bellon, N., Mallet, S., Aubert, H., Vera, C., Achour, L., Thénié, C., Prescilla, R., Abasq-Thomas, C., & Barbarot, S. (2025). Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70268

Vancouver

Lasek A, Bellon N, Mallet S, Aubert H, Vera C, Achour L, et al. Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.70268

BibTeX
@article{Lasek2025,
  author = {Lasek, Audrey and Bellon, Nathalia and Mallet, Stéphanie and Aubert, Hélène and Vera, Carine and Achour, Lamia and Thénié, Claire and Prescilla, Randy and Abasq-Thomas, Claire and Barbarot, Sébastien},
  title = {Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  doi = {10.1111/jdv.70268}
}
Kostenlos starten →